MAUDE Adverse Event Report: C.R. BARD, INC. (COVINGTON) -1018233 BARD® INLAY® URETERAL STENT WITH HYDROGLIDE¿ GUIDEWIRE

Catalog Number	777626
Medical Device Problem Code	Material Fragmentation (1261)
Health Effect - Clinical Code	Exposure to Body Fluids (1745)
Date of Event	01/07/2025
Type of Reportable Event	Serious Injury
Event or Problem Description
It was reported that unpacked and opened the stent and found that the head end of the stent was broken and unusable.Patient has been exposed to hazardous materials, blood or body fluids.It was unknown what medical intervention was provided.
Additional Manufacturer Narrative
The investigation is still in progress.Once the investigation is complete a supplemental report will be filed.Udi format updated with available product information per gudid.H11: section a through f - the information provided by bd represents all the known information at this time.Despite good faith efforts to obtain additional information, the complainant / reporter was unable or unwilling to provide any further patient, product, or procedural details to bd.
Event or Problem Description
It was reported that unpacked and opened the stent and found that the head end of the stent was broken and unusable.Patient has been exposed to hazardous materials, blood or body fluids.It was unknown what medical intervention was provided.
Additional Manufacturer Narrative
The reported event is confirmed cause unknown due to (b)(4).Visual evaluation noted received 1 ureteral stent with push catheter and suture in opened packaging with stent broken towards the pigtail end.Sample was sent to supplier for further evaluation however per supplier memo an investigation was not initiated for the current set of reported stent breakage cases because the majority of the affected lots exhibit the same known and previously investigated failure mode.The breakage pattern, location, and contributing factors are consistent with prior occurrences that have already undergone thorough root cause analysis.Also received one photo sample that shows top view of stent on top of product packaging.Damage to the stent may occur because of adverse handling and/or shipping conditions outside of expected limits.No actions can be taken at this time since a root cause was not identified.A dhr review is not required, as the information needed to investigate the issue is already determined without reviewing the dhr.The instructions for use were found adequate and state the following: precautions: 1.For single use only.Do not resterilize.Do not use if the package or product is damaged.2.Improper handling technique can seriously weaken the stent.Acute bending or overstressing during placement could result in subsequent separation of the stent at the point of stress after a prolonged indwelling period.3.Suture may be cut off prior to stent placement.Remove suture prior to placement for pediatric patients.4.Exercise care.Tearing of the stent can be caused by sharp instruments.5.Ureteral stents should be checked periodically for signs of encrustation and proper function.Periodic checks of the stent by cystoscopic and/or radiographic procedures are recommended at intervals deemed to be appropriate by the physician in consideration of the individual patient's condition and other patient specific factors.When long-term use is indicated, it is recommended that indwelling time not exceed 365 days.The stent is not intended as a permanent indwelling device.* 6.Care should be exercised when removing the stent from inner polybag so as not to cause tearing or fragmentation.F avoid improper handling of stent such as bending, kinking, tearing, etc.Misuse could damage the overall integrity of the stent.Care should be exercised when removing the stent from the inner polybag to eliminate tearing or fragmentation.(2) avoid improper handling which may affect the integrity of this device, including bending, kinking, or tearing.(3) exercise caution to avoid damaging the stent with sharp instruments.This may cause this device to tear, break, or fragment.(8) care should be exercised when removing the stent to eliminate tearing or fragmentation.(2) avoid improper handling which may affect the integrity of this device, including bending, kinking, or tearing.(3) exercise caution to avoid damaging the stent with sharp instruments.This may cause this device to tear, break, or fragment.(8) care should be exercised when removing the stent to eliminate tearing or fragmentation.(2) avoid improper handling of stent such as bending, kinking, tearing, etc.Misuse could damage the overall integrity of the stent.(3) avoid contact with sharp edges as this may cause damage to the stent.If grasping device is used, the stent should be removed from ureter first.Tearing of the stent can be caused by sharp instruments.(8) care should be exercised when removing the stent to eliminate tearing or fragmentation.Precautions: 1.For single use only.Do not resterilize.Do not use if the package or product is damaged.2.Improper handling technique can seriously weaken the stent.Acute bending or overstressing during placement could result in subsequent separation of the stent at the point of stress after a prolonged indwelling period.3.Remove suture prior to placement for pediatric patients.4.Exercise care.Tearing of the stent can be caused by sharp instruments.5.All stents will be subjected to varying degrees of encrustation when placed in the urinary tract.Periodic checks of the stent by cystoscopic and radiographic means are recommended.When encrustation is severe enough to potentially occlude the stent, replace it with a new one.It is recommended that a single stent not remain indwelling more than four (4) weeks.The stent may be replaced with a new stent if the patient's status permits.6.Care should be exercised when removing the stent so as not to cause tearing or fragmentation.Udi format updated with available product information per gudid.H11: section a through f - the information provided by bd represents all the known information at this time.Despite good faith efforts to obtain additional information, the complainant / reporter was unable or unwilling to provide any further patient, product, or procedural details to bd.

• Brand Name: BARD® INLAY® URETERAL STENT WITH HYDROGLIDE¿ GUIDEWIRE
• Common Device Name: URETERAL STENT
• Manufacturer (Section D): C.R. BARD, INC. (COVINGTON) -1018233; 8195 industrial blvd; covington 30014
• Manufacturer (Section G): C.R. BARD, INC. (COVINGTON) -1018233; 8195 industrial blvd; covington 30014
• Manufacturer Contact: xeeroy rada ; 8195 industrial blvd; covington 30014 ; 7707846100
• MDR Report Key: 21547546
• Report Number: 1018233-2025-01531
• Device Sequence Number: 20594661
• Product Code: FAD
• UDI-Device Identifier: 10801741014557
• UDI-Public: (01)10801741014557(11)230111(17)270428(10)NGGZ2735
• Combination Product (Y/N): N
• Initial Reporter Country: CH
• PMA/510(K) Number: K983498
• Number of Events Summarized: 1
• Summary Report (Y/N): N
• Reporter Type: Manufacturer
• Report Source: Other,Company Representative
• Initial Reporter Occupation: Physician
• Type of Report: Initial,Followup
• Report Date (Section B): 08/11/2025

1 Device was Involved in the Event

1 Patient was Involved in the Event

• Is this an Adverse Event Report?: Yes
• Is this a Product Problem Report?: No
• Operator of Device: Health Professional
• Device Catalogue Number: 777626
• Device Lot Number: NGGZ2735
• Was Device Available for Evaluation?: Device Returned to Manufacturer
• Date Returned to Manufacturer: 02/19/2025
• Is the Reporter a Health Professional?: Yes
• Type of Report(Section G): Thirty-Day
• Initial Date Received by Manufacturer: 02/19/2025
• Supplement Date Received by Manufacturer: 08/12/2025
• Initial Report FDA Received Date: 03/07/2025
• Supplement Report FDA Received Date: 08/18/2025
• Was Device Evaluated by Manufacturer? (Y/N): Yes
• Date Device Manufactured: 01/11/2023
• Is the Device Labeled for Single Use? (Y/N): Yes
• Is This a Single-Use Device that was Reprocessed and Reused on a Patient? (Y/N): No
• Usage of Device: Initial
• Patient Sequence Number: 1
• Outcome Attributed to Adverse Event: Other
• Patient Sex: Unknown